
ADPT Valuation
Adaptive Biotechnologies Corp
- Overview
- Forecast
- Valuation
- Earnings
ADPT Relative Valuation
ADPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADPT is overvalued; if below, it's undervalued.
Historical Valuation
Adaptive Biotechnologies Corp (ADPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.90 is considered Undervalued compared with the five-year average of -12.61. The fair price of Adaptive Biotechnologies Corp (ADPT) is between 538.70 to 542.15 according to relative valuation methord. Compared to the current price of 13.13 USD , Adaptive Biotechnologies Corp is Undervalued By 97.56%.
Relative Value
Fair Zone
538.70-542.15
Current Price:13.13
97.56%
Undervalued
-19.97
PE
1Y
3Y
5Y
Trailing
Forward
-78.78
EV/EBITDA
Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBITDA of -78.78. The 5-year average EV/EBITDA is -18.02. The thresholds are as follows: Strongly Undervalued below -51.92, Undervalued between -51.92 and -34.97, Fairly Valued between -1.06 and -34.97, Overvalued between -1.06 and 15.89, and Strongly Overvalued above 15.89. The current Forward EV/EBITDA of -78.78 falls within the Strongly Undervalued range.
-20.56
EV/EBIT
Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBIT of -20.56. The 5-year average EV/EBIT is -10.56. The thresholds are as follows: Strongly Undervalued below -30.15, Undervalued between -30.15 and -20.36, Fairly Valued between -0.77 and -20.36, Overvalued between -0.77 and 9.03, and Strongly Overvalued above 9.03. The current Forward EV/EBIT of -20.56 falls within the Undervalued range.
8.11
PS
Adaptive Biotechnologies Corp. (ADPT) has a current PS of 8.11. The 5-year average PS is 14.18. The thresholds are as follows: Strongly Undervalued below -17.13, Undervalued between -17.13 and -1.47, Fairly Valued between 29.83 and -1.47, Overvalued between 29.83 and 45.49, and Strongly Overvalued above 45.49. The current Forward PS of 8.11 falls within the Historic Trend Line -Fairly Valued range.
-45.85
P/OCF
Adaptive Biotechnologies Corp. (ADPT) has a current P/OCF of -45.85. The 5-year average P/OCF is -16.84. The thresholds are as follows: Strongly Undervalued below -47.37, Undervalued between -47.37 and -32.10, Fairly Valued between -1.58 and -32.10, Overvalued between -1.58 and 13.68, and Strongly Overvalued above 13.68. The current Forward P/OCF of -45.85 falls within the Undervalued range.
-579.08
P/FCF
Adaptive Biotechnologies Corp. (ADPT) has a current P/FCF of -579.08. The 5-year average P/FCF is -36.87. The thresholds are as follows: Strongly Undervalued below -207.42, Undervalued between -207.42 and -122.14, Fairly Valued between 48.41 and -122.14, Overvalued between 48.41 and 133.68, and Strongly Overvalued above 133.68. The current Forward P/FCF of -579.08 falls within the Strongly Undervalued range.
Adaptive Biotechnologies Corp (ADPT) has a current Price-to-Book (P/B) ratio of 11.27. Compared to its 3-year average P/B ratio of 3.39 , the current P/B ratio is approximately 233.03% higher. Relative to its 5-year average P/B ratio of 4.64, the current P/B ratio is about 142.74% higher. Adaptive Biotechnologies Corp (ADPT) has a Forward Free Cash Flow (FCF) yield of approximately -4.19%. Compared to its 3-year average FCF yield of -18.73%, the current FCF yield is approximately -77.62% lower. Relative to its 5-year average FCF yield of -14.34% , the current FCF yield is about -70.77% lower.
11.16
P/B
Median3y
3.39
Median5y
4.64
-4.09
FCF Yield
Median3y
-18.73
Median5y
-14.34
Competitors Valuation Multiple
The average P/S ratio for ADPT's competitors is 1392.84, providing a benchmark for relative valuation. Adaptive Biotechnologies Corp Corp (ADPT) exhibits a P/S ratio of 8.11, which is -99.42% above the industry average. Given its robust revenue growth of 36.33%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ADPT increased by 180.43% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.34 to -16.21.
The secondary factor is the Revenue Growth, contributed 36.33%to the performance.
Overall, the performance of ADPT in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

NXRT
NexPoint Residential Trust Inc
34.510
USD
+1.83%

BFC
Bank First Corp
129.920
USD
-0.19%

AHH
Armada Hoffler Properties Inc
7.280
USD
+0.55%

PGRE
Paramount Group Inc
7.200
USD
+1.84%

TIXT
TELUS International (CDA) Inc
3.880
USD
+1.31%

DLX
Deluxe Corp
19.660
USD
+1.39%

OPK
OPKO Health Inc
1.380
USD
-2.82%

SEAT
Vivid Seats Inc
17.750
USD
+4.60%

PHVS
Pharvaris NV
21.650
USD
-5.21%

GOOS
Canada Goose Holdings Inc
12.980
USD
-1.52%
FAQ

Is Adaptive Biotechnologies Corp (ADPT) currently overvalued or undervalued?
Adaptive Biotechnologies Corp (ADPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.90 is considered Undervalued compared with the five-year average of -12.61. The fair price of Adaptive Biotechnologies Corp (ADPT) is between 538.70 to 542.15 according to relative valuation methord. Compared to the current price of 13.13 USD , Adaptive Biotechnologies Corp is Undervalued By 97.56% .

What is Adaptive Biotechnologies Corp (ADPT) fair value?

How does ADPT's valuation metrics compare to the industry average?

What is the current P/B ratio for Adaptive Biotechnologies Corp (ADPT) as of Aug 30 2025?

What is the current FCF Yield for Adaptive Biotechnologies Corp (ADPT) as of Aug 30 2025?

What is the current Forward P/E ratio for Adaptive Biotechnologies Corp (ADPT) as of Aug 30 2025?
